Skip to main content
OpenTrials
Completed

NCT Number: NCT06420011

FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage

FAITH study is a multicentre retrospective analysis study that aims to understand the burden of ICH related to FXa inhibitors and the current treatment approaches in country/countries where specific reversal agents are not available yet. The results of this analysis will improve our understanding of FXa inhibitor-related ICH, its socioeconomic impact and factors associated with negative outcomes in real-world settings. The insights gained can inform clinical decision making and potentially lead to strategies to optimise the use of FXa inhibitors, increase the availability of specific reversal agents and improve patient safety and outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Buenos Aires, Argentina

Loading trial locations.

About this study

FAITH is a retrospective, non-interventional, multicentre cohort study that will retrieve the data from medical records of adult patients who were hospitalised with confirmed diagnosis of ICH while being treated with FXa inhibitors. The primary objectives of the study is to describe the characteristics and hospital outcomes of hospitalised patients with FXa inhibitors-related ICH in real-world settings. Data of consecutive patients admitted on or after 1 January 2021 and by 30 June 2023 will be retrieved. The index date is defined as the date of hospital admission.The identification of ICH will be based on the CT/MRI scan records and according to the ICD-10-CM diagnosis code. To establish the causal relation between FXa and ICH, the study will include only patients who were determined in the medical records to have taken oral FXa inhibitors.The historical data will be followed up from the index date (the date of hospital admission) until the earliest date of death, lost to follow-up or up to 6 months.The 6-month follow-up period will allow for the assessment of the disability rate and the need for supportive care among survivors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women ≥ 18 years of age at the time of hospital admission.
  • Patients presented with a spontaneous or traumatic haemorrhage into any intracranial compartment. The diagnosis of ICH will be based on Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan and according to the ICD-10-CM diagnosis code.
  • Patients who were determined in the medical records to have taken a dose of oral FXa inhibitors within 24 hrs before hospital presentation that warranted reversal of anticoagulant activities.

Exclusion criteria

  • Patients who were treated with andexanet alfa.
  • Patients who were enrolled in any clinical trials during the study period.

Treatment and study plan

Primary outcomes

  1. Patient characteristics

    Time frame: Index day (Date of hospitalization) to 24hours

    Age of the patients at the time of hospital admission (years) is recorded on Index day within 24 hours of hospitalization

  2. Patient Characteristics

    Time frame: Index day (Date of hospitalization) to 24hours

    Race (Middle Eastern, Asian, other) of the eligible patients is collected

  3. Sociodemographic Characteristics of eligible patients

    Time frame: Index day (Date of hospitalization) to 24hours

    Sociodemographic characteristics like Sex (Male or Female) of the eligible patients is recorded on Index day

  4. Sociodemographic Characteristics

    Time frame: Index day (Date of hospitalization) to 24hours

    Sociodemographic characteristics like nationality of the eligible patients info is collected on Index day

  5. Clinical characteristics

    Time frame: Index day (Date of hospitalization) to 24hours

    Comorbidities info of the eligible patients is recorded on Index day

  6. Clinical Characteristics

    Time frame: Index day (Date of hospitalization) to 24hours

    Clinical characteristics like BMI in Kg/m2 of the eligible patients is recorded on Index day

  7. FXa inhibitor characteristics

    Time frame: Time of last Fxa inhibitor dose to the time of hospital admission of maximum 24 hours

    At index date the following FXa inhibitor characteristics will be described :

    Indication ,type and dose pf FXa Inhibitor

  8. ICH characteristics

    Time frame: Index day to 1 week

    The primary ICH characteristics like type, site and presence of multicompartment haemorrhage during hospitalisation from Index date to 24hours

  9. GCS score

    Time frame: Index day to 24hours

    The GCS is scored between 3 and 15. 3 being the worst and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M)

  10. mRS score

    Time frame: Index day to 24 hours

    mRS score recorded within 24 hours on Index date The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or others causes of neurological disability. It is scored from: 0=No symptoms at all

    • No significant disability
    • Slight disability
    • Moderate disability
    • Moderately severe disability 5=Severe disability

    6=death

  11. NIHSS score

    Time frame: Index date up to 24 hours

    NIHSS score recorded within 24 hours on the Index date

    Scores range from 0 to 42, with higher scores indicating greater severity. Stroke severity may be stratified on the basis of NIHSS scores as follows:

    Very Severe: >25 Severe: 15 - 24 Mild to Moderately Severe: 5 - 14 Mild: 1 - 5

  12. Haematoma volume

    Time frame: Index day to 24 hours

    Haematoma volume based on baseline Imaging scans taken within 24 hours on the index date

  13. BP (Systolic and Diastolic)

    Time frame: Index day to 72 hours

    BP at Index date during hospital admission and in 6, 24, and 72 hours

  14. Antihypertensive treatment

    Time frame: Index day to 1 Week

    Antihypertensive treatment patterns during hospitalisation from Index date to 1 week

  15. In-hospital mortality due to any cause

    Time frame: Index date up to the death event during hospital stay (maximum 1 week)

    Number of patients died between index date (date of hospitalization) to Hospital discharge (maximum of 1 week)

  16. Mortality at 30 days, post index event

    Time frame: Index date up to 30 days

    Number of patients died between index date (date of hospitalization) up to 30 days

  17. Mortality at 3 months post index event

    Time frame: Index date up to 3 months

    Number of patients died between index date (date of hospitalization) up to 3 months

  18. Mortality at 6 months post index event

    Time frame: Index date up to 6 months

    Number of patients died between index date (date of hospitalization) up to 6 months

  19. Type of discharge disposition

    Time frame: Hospital discharge to Maximum of 6 months

    During the period from the hospital discharge date up to death event or 6 months, whichever occurs first, the following type of hospital discharge disposition will be described for survivors like Home, inpatient rehabilitation facility, nursing home, other hospitals/medical centres

Secondary outcomes

  1. Time from symptoms onset to hospital admission

    Time frame: Baseline (which is the date of hospitalization i.e. Index date) to a maximum of 24 hours

    Time between the onset of the bleeding symptoms to admission of patient in hospital in hours.

  2. Time from Hospital admission to time taken to do Imaging scan

    Time frame: Index day (Date of hospitalization) to Maximum of one hour

    Time between patient hospital admission to the performing of Imaging scan in minutes, less than 1 hour

  3. Time from hospital admission to administration of any haemostatic therapy

    Time frame: Index day (Date of hospitalization) to Maximum of one hour

    Time between patient hospital admission to start of the any haemostatic therapy in minutes, in less than 1 hour

  4. Healthcare resource utilization during hospitalisation

    Time frame: Index day to maximum of 1 week

    The length of ICU stay of eligible patients in days from Index day to maximum of 1 week

  5. Length of hospitalisation in days

    Time frame: Index day to maximum of 1 week

    The length of hospitalisation of eligible patients in days from Index day to maximum of 1 week

  6. Disability rate among survivors

    Time frame: At hospital discharge (Maximum of 1 week from Index day)

    At hospital discharge (Maximum of 1 week from Index day) Modified Rankin Score (mRS) will be described

    Functional outcome assessed with the modified Rankin Scale (mRS) at hospital discharge .The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered of stroke or other causes of neurological disability. It is scored from:

    0=No symptoms at all

    1=No significant disability, 2=Slight disability 3=Moderate disability 4=Moderately severe disability 5=Severe disability 6=death

  7. Disability rate among survivors

    Time frame: Index day to 3 months

    At three months, after the index event (date of hospital admission) Modified Rankin Score (mRS) will be described.

  8. Health care resource utilization after hospital admission up to 6 months

    Time frame: Index date to 6 months

    From the index date to 6 months the following HCRU will be described:

    Need for supportive medical care ,type of supportive care (including rehabilitation services), inpatient rehabilitation, outpatient rehabilitation, including occupational therapists, speech and language pathologists, dietician, nurse, adaptive equipment, everything else.

  9. Health care resource utilization within 6 months after hospital discharge.

    Time frame: Hospital discharge up to 6 months

    From the patient hospital discharge up to 6 months the following HCRU will be described:

    Number of inpatient readmissions after discharge and up to 6 months, Type of ward, Number of days of hospitalization Reason for readmission and Medications.

  10. Disability rate among survivors

    Time frame: Index day to Maximum of 6 months

    At six months after the index event (date of hospital admission) Modified Rankin Score (mRS) will be described.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Real-World, Observational, Multicentre Retrospective Analysis to Evaluate the Clinical Characteristics, Medical Management and Outcomes of Hospitalised Patients With Factor XA Inhibitor-Related InTracranial Haemorrhage (FAITH)

Acronym: FAITH

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
May 17, 2024
Registry last updated
Oct 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.